---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030066"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2022-11-01T23:59:59+00:00"
generated_at: "2026-06-22T18:57:17.905561+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharmaceuticals appoints Dr. Bette Jacobs to Board, fills vacancy

## Summary
- Appointed Dr. Bette Jacobs as independent director to fill vacancy left by William Adkins, effective Oct 28, 2022.
- Dr. Jacobs will serve on Audit Committee and Nominating and Corporate Governance Committee.
- Compensation includes $25,000 annual cash and $100,000 in RSUs vesting over three years.
- Board amended bylaws to reduce director term from three years to one year.

## SEC filing metadata
- accession: 0001493152-22-030066
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2022-11-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/0001493152-22-030066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030066
- JSON: https://secwatch.observer/filing/0001493152-22-030066.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030066.txt

## Key facts
- Executive change
  William Adkins departed as Director at Shuttle Pharmaceuticals Holdings, Inc..
  - Action: vacated
  - Role: Director
  source text: seat vacated by William Adkins, an independent director, whose term of service ended effective as of October 28, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/0001493152-22-030066-index.htm
- Executive change
  Bette Jacobs was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 28, 2022, the board of directors (the “Board”) of Shuttle Pharmaceuticals Holdings, Inc., a Delaware Corporation (the “Company”), based upon the recommendation of the Board’s Nominating and Corporate Governance Committee, approved the appointment of Bette Jacobs, Ph.D. to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/0001493152-22-030066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.